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Exosomes are membrane-enclosed nanovesicles (30–150 nm) that shuttle active
cargoes between different cells. These tiny extracellular vesicles have been recently
isolated from mesenchymal stem cells (MSCs) conditioned medium, a population of
multipotent cells identified in several adult tissues. MSCs paracrine activity has been
already shown to be the key mediator of their elicited regenerative effects. On the
other hand, the individual contribution of MSCs-derived exosomes for these effects
is only now being unraveled. The administration of MSCs-derived exosomes has been
demonstrated to restore tissue function in multiple diseases/injury models and to induce
beneficial in vitro effects, mainly mediated by exosomal-enclosed miRNAs. Additionally,
the source and the culture conditions of MSCs have been shown to influence the
regenerative responses induced by exosomes. Therefore, these studies reveal that
MSCs-derived exosomes hold a great potential for cell-free therapies that are safer
and easier to manipulate than cell-based products. Nevertheless, this is an emerging
research field and hence, further studies are required to understand the full dimension
of this complex intercellular communication system and how it can be optimized to
take full advantage of its therapeutic effects. In this mini-review, we summarize the most
significant new advances in the regenerative properties of MSCs-derived exosomes and
discuss the molecular mechanisms underlying these effects.
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INTRODUCTION
Exosomes are the tiniest extracellular vesicles (EVs) involved in a complex intercellular
communication system (Lamichhane et al., 2015). EVs are categorized as exosomes due to their
endocytic origin, in contrast to microvesicles that are formed from budding of the plasma
membrane and apoptotic bodies derived from fragments of dying cells (Merino et al., 2016). Along
with other EVs, exosomes are released by several cell types, carrying active signals that are able
to influence the activity of recipient cells. Since its discovery, this extracellular communication
system has been hijacked in several ways. Firstly, exosome surface markers and molecular cargoes
have been worthily challenged as potential diagnostic biomarkers (Muller, 2012; Dorayappan
et al., 2016; Escudero et al., 2016). Secondly, due to their low immunogenicity, long half-life in
circulation and ability to cross the brain-blood barrier (BBB), exosomes have also been explored
as a nanodelivery system of therapeutic signals, such as small interfering RNAs (Sun et al., 2010;
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Alvarez-Erviti et al., 2011; Kalani et al., 2014). Finally,
and surprisingly, unmodified exosomes secreted by stem or
progenitor cells have also shown beneficial effects and have been
put forward as mediators of the regenerative responses elicited,
for instance, by mesenchymal stem cells (MSCs; Lai et al., 2010;
Xin et al., 2012). Indeed, the effects of these cells on tissue
regeneration and repair have been mainly attributed to their
secreted factors (known as secretome) rather than its trans-
differentiation capacity (Teixeira et al., 2013). Having this in
mind, under the scope of the present review we will address the
recent evidences of the regenerative potential of MSCs-derived
exosomes into different pathological conditions.
EXOSOMES AS CELL-SECRETED EVs
Exosomes and microvesicles are the most thoroughly studied
classes of EVs. Both are membrane-enclosed vesicles, surrounded
by a phospholipid layer and packed with cell-type specific
combinations of proteins, lipids, coding, and non-coding RNAs
(Lener et al., 2015). Once released into the extracellular milieu,
EVs can be taken up by target cells of the microenvironment or
carried to distant sites through biological fluids, from which they
have already been isolated, including urine (Royo et al., 2016),
breast milk (Zonneveld et al., 2014), blood (Baranyai et al., 2015),
and cerebrospinal fluid (Street et al., 2012).
In spite of their relative availability, the complexity of the
extracellular environment and the existence of extracellular
RNA in other non-EV carriers, such as protein complexes
and lipoproteins, has encouraged the International Society for
Extracellular Vesicles (ISEV; Lötvall et al., 2014) to establish
minimal requirements for describing EVs, namely: (i) isolation
from extracellular body fluids or conditioned cell culture
medium, with minimal cell disruption; (ii) quantification
of at least one protein from three different categories
(transmembrane or lipid bound extracellular proteins, cytosolic
proteins and intracellular proteins) in the EV preparation; (iii)
characterization of single vesicles within the EV preparation
using at least two different technologies, electron microscopy or
atomic force microscopy (AFM) for imaging and nanoparticle-
tracking analysis, dynamic light scattering, or resistive pulse
sensing for size distribution measurements of EVs (Lötvall et al.,
2014). EVs are further classified as exosomes or microvesicles
based on their intracellular biogenesis pathway. Microvesicles
are originated at the cell surface and released by direct outward
budding of the plasma membrane, whereas exosomes are formed
within multivesicular bodies (MVBs) at the endolysosomal
pathway and secreted upon fusion of MVBs with the plasma
membrane (Figure 1A; Kalani et al., 2014).
Exosomes comprise a homogenous population of nano-sized
vesicles, as their diameter ranges from 30 to 150 nm (Lener et al.,
2015; Willms et al., 2016). Additionally, exosomes are also a
better characterized population of EVs. Exosomal proteins, RNAs
and lipids described in published and unpublished studies have
been cataloged in ExoCarta, a database that aims to identify
specific molecular signatures of tissue/cell-type derived exosomes
(Mathivanan et al., 2012). ALIX and TSG10 have been recognized
as common protein markers for exosome identification, due to
their participation in the endosomal sorting complex required
for transport (ESCRT), as well as membrane proteins of the
tetraspanin family, such as CD9, CD63, CD81, CD82 (Figure 1B;
Wubbolts et al., 2003; Hurley and Odorizzi, 2012).
Conventional methods for isolation of exosomes include
ultracentrifugation, density gradient separation, chromatography
and immunoaffinity capture (IAC) techniques as well as
commercial kits, such as polymer-based precipitation. Despite
being all capable to isolate vesicles with exosomal diameter and
markers, some authors have suggested IAC as the most effective
method to isolate exosomes, based on the number of exosome-
related proteins identified on the purified fraction (Tauro et al.,
2012; Greening et al., 2015). However, there is an ongoing
debate on the ability of these methods to fully separate exosomes
from protein aggregates and other membranous vesicles. The
distinction between microvesicles and exosomes, for instance,
is challenging as a result of the heterogeneity of microvesicles
diameter (50–1000 nm), as well as small amount of protein
markers to clearly categorize EVs produced via budding from
the cell membrane or produced via endosomal compartment.
Therefore, the ISEV (Lötvall et al., 2014) has recommended
cautious interpretation of some exosomal-mediated responses
described so far. In fact, some studies focused on the evaluation
of the individual contribution of exosomes and microvesicles,
report unique effects of exosomes- and microvesicles- enriched
fractions that were obtained through differential centrifugation
steps (Jarmalaviciute et al., 2015; Lopez-Verrilli et al., 2016). Even
within the same population of exosomes, Willms et al. (2016)
have defined two distinct subpopulations of exosomes based on
distinct particles sizes that enclose different protein and RNA
compositions and, therefore, yield different effects on recipient
cells. Taken together, these studies show that the improvement
of current isolation methods and a better understanding of
exosomal biology are of key importance to clearly determine the
therapeutic effects of exosomes.
MSCs and MSCs-DERIVED EXOSOMES
The regenerative potential of MSCs and particularly of their
secretome has been extensively reviewed (Teixeira et al., 2013;
Salgado et al., 2015; Konala et al., 2016). MSCs are a population
of adult multipotent cells with the ability to self-renew and
differentiate into mesenchymal lineages, namely osteoblasts,
chondrocytes, and adipocytes (Pittenger et al., 1999). Even
though originally isolated from bone marrow (BM-MSCs;
Friedenstein et al., 1976), MSCs have been successfully identified
and isolated from other adult tissues, such as adipose tissue
(ASCs), dental pulp, placenta, amniotic fluid, umbilical cord
blood, umbilical cord Wharton’s jelly (WJ-MSCs) and its
perivascular region (HUCPVCs), and even the brain (Teixeira
et al., 2013). MSCs differentiation potential has been explored
in cell replacement strategies aiming to restore compromised
adult mesenchymal tissues, although some authors have also
reported its differentiation into ectodermal lineages (Donega
et al., 2014; Takeda and Xu, 2015; Bagher et al., 2016).
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FIGURE 1 | Origin, composition, and therapeutic potential of MSCs-derived exosomes. (A) Endocytic origin of MSCs-derived exosomes and influence of
tissue from which MSCs are isolated and culture conditions on exosome secretion profile. (B) Size and composition of exosomes, depicting in gray the molecular
markers of exosomes (CD9, 63, 81, and 82, ALIX and TSG10). (C) Therapeutic potential and suggested miRNAs and proteins mediating the regenerative effects of
MSCs-derived exosomes. MSCs, mesenchymal stem cells; RER, rough endoplasmic reticulum; GC, Golgi complex; MVBs, multivesicular bodies; NEP, Neprilysin;
ESC, embryonic stem cells; iPSCs, induced pluripotent stem cells.
Nonetheless, the paradigm of MSCs-mediated regeneration has
been shifting toward a secretome-based paracrine activity, rather
than its cellular engraftment and differentiation. Indeed, it has
been widely accepted that MSCs secrete bioactive factors with
strong immunomodulatory activities, which are also able to
inhibit fibrosis and apoptosis, enhance angiogenesis and promote
neuronal survival and differentiation (Caplan and Dennis, 2006;
Teixeira et al., 2015). As a result, the use of MSCs conditioned
medium (CM) has been put forward as a cell-free strategy with
promising therapeutic effects, including reduction of myocardial
infarct size (Timmers et al., 2007), trophic support to injured liver
(van Poll et al., 2008) and protective effects on acute kidney injury
(Zarjou et al., 2011).
Initial studies from Timmers et al. (2007) on ischemia and
reperfusion injury, demonstrated that only the fraction of the
CM containing products> 1000 kDa provided cardioprotection.
At that time, the authors suggested the existence of a complex
of proteins and lipids (with a predicted diameter of 50–
100 nm) mediating MSCs paracrine activity. Three years later,
the same group (Lai et al., 2010) isolated and characterized
exosomes from human ESC-derived MSCs CM, for the first
time. These spherical structures were readily visualized at
the CM by electron microscopy, and further precipitated by
ultracentrifugation. The presence of exosomes was also evidenced
by the enrichment in plasma membrane phospholipids, such
as cholesterol, sphingomyelin and phosphatidylcholine, as well
as coprecipitation of exosome-associated proteins, including
CD81, CD9, and ALIX. Thenceforward, a novel perspective of
intercellular mediation of tissue repair was highlighted.
Enclosed RNA molecules have been described as the
main messengers of the responses induced by exosomes.
Indeed, coding mRNA molecules packed within exosomes are
functionally translated at recipient cells (Valadi et al., 2007).
Notwithstanding, small non-coding RNAs (20–30 nucleotides),
and particularly microRNAs (miRNA), have been described as
major mediators of cell–cell communication as they are able to
regulate gene expression via miRNA degradation and repression
of translation (Ha and Kim, 2014). A small RNA profiling of
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BM-MSCs and ASCs exosomes, recently performed by Baglio
et al. (2015), revealed that, along with miRNA, MSCs exosomes
are highly enriched in transfer RNA (tRNA) species that can
function as miRNAs. Furthermore, while cellular small RNA
expression profile is not donor- or tissue-specific, exosomal small
RNA content seems to be greatly influenced by cell differentiation
status, i.e., donor variability, and cell type (Baglio et al., 2015).
The authors suggest that exosomal-enclosed small RNAs released
by MSCs may distinctly control the microenvironment in their
resident niches through a balance between proliferation and
differentiation (Baglio et al., 2015). This study shed light on
possible regulatory mechanisms of MSCs paracrine activity
responsible for tissue-specific MSCs CM regenerative properties
that were previously described by our laboratory (Ribeiro et al.,
2012). Recently, tissue-specific responses were also described
for exosomes isolated from different sources. For instance,
ASCs-derived exosomes seem to be more effective in degrading
Aβ in an in vitro model of Alzheimer’s disease (AD), when
compared to BM-MSCs-derived exosomes (Katsuda et al., 2013),
whereas neurite outgrowth response appears to be enhanced
by exosomes released by menstrual fluid derived MSCs, when
compared to umbilical cord, chorion and bone marrow (Lopez-
Verrilli et al., 2016). These studies unveil the need to further
distinguish the functional properties of exosomes released by
MSCs isolated from different adult tissues to better understand
their individual regenerative potential. The influence of gender
on MSCs exosomal secretion profile should be also taken into
account in future studies.
MSCs-DERIVED EXOSOMES APPLIED
TO TISSUE REGENERATION
Since the report of MSCs-derived exosomes, a growing amount of
studies have explored their regenerative potential using different
in vitro and in vivo models (Figure 1C). In the present report we
will focus on those that, in our opinion, are the most relevant.
Cardiovascular System
MSCs-derived exosomes were firstly suggested as
cardioprotective agents by Kleijn’s group (Lai et al., 2010).
Subsequently, other studies have addressed the proangiogenic
effects of MSCs exosomes as a mechanism of tissue repair
upon ischemia. Bian et al. (2014) firstly showed that MSCs
secrete a large quantity of exosomes under hypoxia and serum
deprivation. In a similar ischemic conditioning, MSCs were
shown to secrete exosomes enriched with miR-22, which led
to the reduction of apoptosis and cardiac fibrosis through a
direct targeting of methyl CpG binding protein 2 (Mecp2;
Feng et al., 2014). In line with this, a recent analysis of the
proteomic profile of MSCs-derived exosomes cultured under
these conditions revealed a robust profile of angiogenic signaling
proteins, including NFkB interacting proteins, which mediate
tubule formation upon low to medium doses (1–10 µg/mL)
treatment of MSCs-derived exosomes (Anderson et al., 2016).
Importantly, several authors have demonstrated that
internalization of MSCs-derived exosomes by endothelial cells
stimulate proliferation, migration and tube formation (in vitro)
and promote angiogenesis when injected intramyocardially
in acute myocardial infarction rat models (Bian et al., 2014;
Teng et al., 2015). Hu et al. (2015) have also evidenced that
intramuscular injection of exosomes secreted by human induced
pluripotent stem cells-derived MSCs (iPSCs-derived MSCs)
promote endothelial cell migration, proliferation, and tube
formation through the activation of angiogenesis-related
molecule expression (VEGF, TGFB1, and Angiogenin), leading
to an increase of microvessel density and blood perfusion in a
mouse hind-limb ischemic model.
In a follow-up study, Arslan et al. (2013) have shown that
a single intravenous administration of exosomes was effective
in enhancing cardiac function and geometry after myocardial
infarction due to bioenergetics reestablishment (increased
ATP production), oxidative stress reduction and pro-survival
signaling activation (enhanced PI3K/Akt signaling). A similar
outcome was presented by Wang et al. (2015) in polymicrobial
sepsis.
Asahara’s group (Zhang et al., 2016b) have used the
proliferative and angiogenic potential of MSCs exosomes to
condition cardiac stem cells (CSC) in vitro, which when
transplanted into a rat model of myocardial infarction were able
to preserve cardiac function.
Kidney
Acute kidney injury has also been effectively treated with
MSCs exosomes. In vitro, treated renal tubular epithelial cells
exhibited increased activation of extracellular-signal-regulated
kinase (ERK)1/2 pathway and thus increased cell proliferation
(Zhou et al., 2013). In vivo, after direct injection into injured
kidneys (cisplatin-induced acute kidney injury rat model),
hucMSCs-Ex were shown to be incorporated into the tubular
epithelial cells and to promote functional and morphologic
recovery by reducing oxidative stress and suppressing apoptosis
(Zhou et al., 2013). Recently, Jiang et al. (2016), characterized
urine-derived stem cells as multipotent MSCs (USCs) and a
source of exosomes, and demonstrated that when intravenously
injected they were able to reduce kidney deficits in type I diabetic
rats.
Liver
HucMSCs-Ex have also been explored as a treatment to fibrotic
liver disease, which can be induced by viral hepatitis, alcohol,
drugs, metabolic diseases, and autoimmune attack of hepatic
cells (Li et al., 2013). Li et al. (2013), have demonstrated that
after liver fibrosis [induced by carbon tetrachloride (CCl4)], the
delivery of exosomes into the liver reduced fibrosis through the
inactivation of the transforming growth factor (TGF)-β 1/Smad
signaling pathway, as well as through the inhibition of epithelial-
to-mesenchymal transition of hepatocytes. Using the same mouse
model, Hyun et al. (2015) demonstrated that chorionic plate-
derived MSCs retained miR-125b in exosomes which suppressed
the Hedgehog activation and consequently liver fibrosis. In
addition to this, the hepatic regenerative potential of hESC-
derived MSCs exosomes was also evidenced using two in vitro
models of liver injury [acetaminophen (APAP)- and (2) hydrogen
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peroxide (H2O2)], in which treatment resulted in increased anti-
apoptotic and proliferative responses (Tan et al., 2014).
Immune System
In accordance to well-known MSCs immunomodulatory effects,
MSCs exosomes have also been described as immunological
active agents as they induce high levels of anti-inflammatory
cytokines, in contrast to decreased levels of pro-inflammatory
molecules, providing a rationale for the use of exosomes
for the treatment of immune disorders (Zhang et al., 2014).
In addition, MSCs exosomes can also inhibit macrophage
activation by suppressing Toll-like receptor signaling,
providing a physiologically relevant context for the innate
immunomodulatory activity of MSCs (Phinney et al., 2015). In
a mouse model of hypoxic pulmonary hypertension, Lee et al.
(2012) demonstrated that the intravenous delivery of exosomes
derived from MSCs CM suppress hypoxic inflammation
by inhibition of pro-proliferative pathways, such as STAT3
phosphorylation.
Musculoskeletal System
In the context of bone regeneration, Narayanan et al. (2016)
demonstrated the potential of exosomes released by MSCs
cultured under osteogenic conditions. In a 2D and in a 3D (type I
collagen hydrogels) culture these exosomes triggered osteogenic
differentiation of undifferentiated MSCs. In vivo, when implanted
subcutaneously in a grade collagen membrane, “osteogenic”
exosomes promoted calcium deposition and calcium phosphate
nucleation. In addition, Nakamura et al. (2015) have also
suggested that MSCs-derived exosomes are able to promote
skeletal muscle regeneration by enhancing myogenesis and
angiogenesis and have considered exosome-enclosed miR-494 an
important mediator of this response.
Nervous System
MSCs-secretome has shown therapeutic benefits for the
treatment of neurological and neurodegenerative diseases.
Accordingly, Xin et al. (2012, 2013b) have demonstrated that
miR-133b, increased in MSCs exposed to ischemic cerebral
extracts, is transferred to neurons and astrocytes via exosomes
and promotes neurite outgrowth and functional recovery in
a middle cerebral artery occlusion model. In another study,
these authors (Xin et al., 2013a) demonstrated that after stroke,
the intravenous administration of cell-free MSCs-generated
exosomes also enhances neurite remodeling, neurogenesis
and angiogenesis and therefore, improves functional recovery.
Similar encouraging outcomes were obtained in a traumatic brain
injury model, in which intravenous administration of MSCs-
generated exosomes enhanced angiogenesis and neurogenesis,
reduced inflammation and improved spatial learning and
sensimotor function (Zhang et al., 2015; Kim et al., 2016).
Katsuda et al. (2013) have provided an important role
for ASCs-derived exosomes in the context of AD, as these
express high levels of Neprilysin (NEP), the most important
Aβ-degrading enzyme in the brain. NEP-loaded exosomes were
shown to be efficiently transferred to neuroblastoma cells and led
to the decrease of both extracellular and intracellular Aβ levels. In
another in vitro neurodegeneration model, exosomes released by
dental pulp-derived MSCs on a 3D culture, rescued dopaminergic
neurons from 6-OHDA induced apoptosis, thereby providing a
possible treatment of Parkinson’s disease (Jarmalaviciute et al.,
2015).
Other studies have focused on non-diseased in vitro models
to demonstrate MSCs-derived exosomes potential for neuronal
differentiation. For instance, Lee et al. (2014) reported that BM-
MSCs deliver miR-124 and miR-145 to human neural progenitor
cells (NPCs) and astrocytes via contact independent and
exosome-dependent processes, which alter gene expression in the
recipient neural cells. Indeed, exosomal-mediated axonal growth
seems to depend on argonaut 2 protein, a miRNA machinery
protein, whereas internalization of BM-MSCs exosomes in cell
bodies and axons has been suggested to occur via SNARE
complex (Zhang et al., 2016a). Lopez-Verrilli et al. (2016)
have recently unraveled the potential of menstrual MSCs
(MenSCs) exosomal-enriched fraction as therapeutic approach in
neurodegenerative pathologies. These authors demonstrated that
MenSC exosomes induced neurite growth in cortical neurons and
had a similar effect to BM-SC exosomes on neurite outgrowth of
dorsal root ganglia neurons.
CONCLUSION AND FUTURE
PERSPECTIVES
MSCs-derived exosomes have emerged, in the last six years,
as an attractive and safe approach for regenerative medicine
applications. Of note, the intravenous administration of these
nanovesicles has not elicited adverse effects. In addition,
MSCs-derived exosomes regenerative effects reinforce the
paradigm of secretome-based paracrine action of MSCs and
support future perspectives for the development of cell-free
therapies that avoid the safety concerns associated to stem cell
transplantation and are less technically difficult to prepare and
deliver. Nevertheless, this is a still developing research area that
needs to be optimized to take full advantage of MSCs-derived
exosomes regenerative potential. For instance, the choice of
MSCs source and their culture conditions must be explored, as
these have been shown to impact the functional properties of the
exosomes.
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